15.3
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration de…
Administered drugs begin to act once the minimum effective plasma level, Cmin, is attained. They remain effective as long as the concentration stays above Cmin.
The duration of drug action depends on the dose size, the drug removal rate, tissue binding, and route of administration.
With an increase in dose, Cmin is achieved rapidly, leading to the drug’s quicker onset and longer duration of action.
As per one-compartment kinetics, the following equation provides plasma drug concentration after an IV bolus. If plasma concentration is Cmin, then t becomes td or duration of the drug effect. Rearranging the equation yields td, with the resulting plot between td and log dose being linear.
As a result, doubling the dose increases the effect duration by one half-life.
However, for drugs having a narrow therapeutic index, doubling the dose may cause toxic effects. Instead, the same dose can be repeated when the drug levels fall.
View the full transcript and gain access to JoVE Core videos
Q1: What is the minimum effective plasma level and why does it matter for drug action?
The minimum effective plasma level (Cmin) is the lowest drug concentration required to produce a therapeutic effect. A drug begins acting once plasma concentration reaches Cmin and remains effective as long as concentration stays above this threshold. When concentration falls below Cmin, the drug no longer elicits a response, defining the end of the drug's duration of action.
Q2: How does increasing a drug dose affect the onset and duration of action?
Increasing the dose allows the minimum effective plasma level to be achieved more rapidly, resulting in faster onset and prolonged duration of action. A larger dose maintains plasma concentration above Cmin for an extended period before elimination reduces it below the therapeutic threshold, extending the overall effect duration.
Q3: What is the relationship between dose doubling and drug effect duration?
According to one-compartment kinetics, doubling the dose increases the effect duration by approximately one half-life. This linear relationship between log dose and duration of effect holds true as long as plasma concentration remains well above Cmin. Understanding the Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration helps predict how dose changes affect drug action time.
Q4: Why is doubling the dose problematic for drugs with a narrow therapeutic index?
Drugs with a narrow therapeutic index have a small margin between effective and toxic doses. Doubling the dose to extend duration may cause plasma concentration to exceed safe levels, resulting in adverse effects. For these drugs, repeating the same dose when levels fall to Cmin provides a safer alternative that maintains efficacy with minimal toxicity risk.
Q5: What factors determine how long a drug remains effective in the body?
Drug action duration depends on dose size, the drug removal rate, tissue binding, and route of administration. These factors collectively determine how quickly the minimum effective plasma level is achieved and how long plasma concentration remains above Cmin before elimination reduces it below the therapeutic threshold.
Q6: How do redistribution and elimination processes affect drug duration?
Drug duration depends on redistribution to poorly perfused tissues and elimination processes. Redistribution moves drug from the site of action to storage tissues, reducing active plasma concentration. Elimination removes drug from the body entirely. Together, these processes determine the rate at which plasma concentration falls below Cmin, ending the drug's therapeutic effect.
Q7: What dosing strategy optimizes drug therapy for narrow therapeutic index drugs?
For drugs with narrow therapeutic indices, administering the same dose when plasma concentration drops to Cmin results in a minimal increase in duration while maintaining safety. This approach avoids the toxicity risk of dose doubling and provides more predictable, controlled therapeutic outcomes compared to increasing dose size.